Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.

Next Previous
Search
Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Age-related macular degeneration; Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ReVIEW
  • Sponsors Stealth BioTherapeutics

    • Most Recent Events

    • 23 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jun 2015 Results were presented in New York City at Stealth second Mitochondrial Science and Medicine Series symposium focused on mitochondria role in ophthalmology according to Stealth BioTherapeutics media release.
    • 25 Jun 2015 Results published in the Stealth BioTherapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top